Innovative solutions to combat viral animal diseases and zoonoses

“A comprehensive analysis of both protective and detrimental immune responses to ASFV is essential for the development of a safe and effective vaccine. “

An infection of dairy cows with the H5N1 avian influenza virus was first observed in the USA in 2024. The milk of the infected animals contained large quantities of infectious viruses.

The SPF-IVI pigs: to study their immune response, the IVI has bred pigs for many years under exceptional experimental sanitary conditions characterised by the absence of swine pathogens. This special sanitary statute is associated with a particularly naïve immune system with a response to ASF virus infection that has enabled fundamental advances described in this project.

African swine fever (ASF) is a major viral disease that affects both domestic and wild pigs. The ASF virus was first detected in Africa, from where it has spread worldwide, causing significant economic losses in the pig sector. In Africa the virus is transmitted by soft-bodied ticks, primarily between African wild pig species such as warthogs, bushpigs and brush-eared pigs. However, these species do not usually become infected. In contrast, ASF infection of domestic pigs or Eurasian wild pigs leads to serious disease, often accompanied by high mortality. Transmission between domestic pigs and Eurasian wild pigs mainly occurs through direct animal-to-animal contact or through contaminated products. There are currently no registered vaccines or treatment options. ASF poses a threat not only to the pig sector, but also to wild pig populations.

Waterfowl are a natural reservoir for influenza A viruses. They excrete large quantities of infectious viruses into the environment via their faeces. This can lead to transmission to other species such as domestic poultry, pigs or mink, which – as intermediate hosts – can play a decisive role in the emergence of influenza pandemics.

Zoonotic flaviviruses are usually transmitted by ticks or mosquitoes and cause severe encephalitis, foetal damage or haemorrhagic fever in humans and animals. Some of these flaviviruses pose a growing threat to humans and animals in Europe due to the increasing spread of vectors (ticks and mosquitoes) as a result of global warming and globalisation. The detection of West Nile virus (WNV) in native mosquitoes in Switzerland in 2022 increases the risk of home-grown cases in animals or humans.

Before the eradication programme was launched, the economic losses due to BVD on Swiss cattle farms amounted to several million Swiss francs per year. This prompted various national breeding associations to call for the eradication of BVD in the Swiss cattle population.

Experiments on the immune cells of the natural host and on animals themselves are essential in order to study these infectious diseases. In vitro models do not yet allow us to assess the mechanisms and severity of a disease associated with a viral strain, or the immune response and the protective effect of potential vaccines. In these cases, therefore, animal experiments are necessary. All animal experiments in Switzerland are subject to a strict licensing procedure under the Federal Act on Animal Protection. First and foremost, in order to respect the first «R» of the 3Rs principle (Replace, Reduce, Refine), a study involving animals is permitted only if no alternative method is available to answer the research questions. Once the absolute necessity of an animal experiment has been established, an independent cantonal commission scrutinises the application. The latter must justify the objectives and the minimum number of animals (Reduce), and show that the methods used respect animal welfare as far as possible (Refine). No licence can be issued until such an assessment has been completed. A weighing up of interests enables us to determine whether an animal experiment may be licensed and carried out.If a question can be answered using permanent animal or human cell lines, or even using an entirely synthetic approach, these must be prioritised, as they minimise the use of animal experiments. However, it is often necessary to use primary cells. To this end, IVI animals undergo regular blood sampling, a procedure that is also subject to licensing and has a severity level of 0. The primary cells obtained in this way are used to:

IVI coronavirus research is conducted in a biosafety level 3 laboratory. Researchers wear full-body protective suits that also cover the head. Virus work is carried out with extreme care using a biological safety cabinet.